A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)

Abstract Background The study is to evaluate the efficacy and safety of combined anlotinib and EGFR-tyrosine kinase inhibitors (TKIs) in patients with advanced non-small cell lung cancer (NSCLC) who had gradual, oligo, or potential progression after previous EGFR-TKIs treatment. Methods We conducted...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Hua-Jun Chen, Hai-Yan Tu, Yanping Hu, Yun Fan, Guowu Wu, Shundong Cang, Yi Yang, Nong Yang, Rui Ma, Gaowa Jin, Ximing Xu, Anwen Liu, Shubin Tang, Ying Cheng, Yan Yu, Chong-Rui Xu, Qing Zhou, Yi-Long Wu
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	BMC 2025-01-01
Ráidu:	Journal of Hematology & Oncology
Fáttát:	EGFR mutation Anlotinib Gradual progression Oligo progression Non-small cell lung cancer
Liŋkkat:	https://doi.org/10.1186/s13045-024-01656-0
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!